A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs BMS 986179 (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb
- 11 Jan 2018 The protocol has been amended to include one more arm in the treatment group ie. the Monotherapy (Dose Expansion) arm.
- 05 Jul 2016 Planned End Date changed from 1 Apr 2020 to 1 May 2020.
- 05 Jul 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Mar 2019.